Cargando…
Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice.
We attempted to induce anti-tumour immunity for rejecting pre-B lymphoma derived from E mu/ret transgenic mice (TGM). We established pre-B-lymphoma cell lines of C57BL/6 x Balb/c background (H-2b/d) into which H-2k alloantigen and C3H background were introduced (retL1-6 and retL6-6), and we inoculat...
Autores principales: | Ichihara, M., Iwamoto, T., Isobe, K., Takahashi, M., Nakayama, A., Pu, M., Dai, Y., Parashar, A., Ohkus, K., Kato, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033753/ https://www.ncbi.nlm.nih.gov/pubmed/7710948 |
Ejemplares similares
-
c-RET Molecule in Malignant Melanoma from Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines
por: Ohshima, Yuichiro, et al.
Publicado: (2010) -
Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.
por: Fabien, N., et al.
Publicado: (1992) -
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023) -
Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993) -
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)